Torrent Pharmaceuticals stock (INE482A01020): shares trade ex-dividend as market focuses on valuation metrics

Torrent Pharmaceuticals shares in India were in focus on 05/29/2026 as the stock traded ex-dividend for a final dividend of ?9 per share for the latest financial year, putting its cash-return profile under the spotlight for investors on the National Stock Exchange of India (NSE) and BSE.

According to an ex-dividend list published by ET Now on 05/29/2026, Torrent Pharmaceuticals was among 13 companies going ex-dividend that day, with the company’s final dividend set at ?9 per share alongside other domestic names such as ICICI Lombard General Insurance, JB Chemicals & Pharmaceuticals and UNO Minda.

On the NSE, Torrent Pharmaceuticals trades under the ticker TORNTPHARM, while on the BSE it is listed under code 500420, with trading in Indian rupees and inclusion in the Pharmaceuticals & Drugs sector, anchoring the company firmly in the Indian equity market.

The stock has also recently seen active derivatives interest, with MarketsMojo highlighting a rise in open interest and stronger trading volumes along with positive price action and an upgrade to a Buy rating, which suggests that the Indian market has been positioning around the stock following its latest results and ahead of dividend-related dates.

The ex-dividend date on 05/29/2026 means that investors purchasing Torrent Pharmaceuticals shares from that session onward on Indian exchanges will not be entitled to the declared final dividend of ?9 per share and that the market may adjust the price to reflect the cash payout flowing out of the company.

For German-based investors, Torrent Pharmaceuticals is also available via trading venues such as Tradegate through secondary listings or certificates, although liquidity and spreads typically remain concentrated in the home market in India where the company’s primary valuation benchmarks are set.

The stock traded actively in recent sessions on the NSE in Indian rupees, and while intraday levels fluctuate, derivative-market commentary from MarketsMojo noted that the share price recently touched an intraday high of around ?4,517.7 before closing with a gain of 0.95 percent on that day, outperforming both its sector and the broader Sensex index as of that report.

As the dividend becomes detached from the shares following the ex-date, investors tend to look more closely at valuation multiples such as price-to-earnings and enterprise-value-based metrics to judge whether the company’s earnings power and cash generation justify the current trading range on Indian exchanges.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Torrent Pharmaceuticals: core business model

Torrent Pharmaceuticals focuses on branded generics and specialty medicines in chronic therapy areas, with growth largely fueled by prescription-driven demand in India and a widening international footprint in regulated and semi-regulated markets.

Valuation metrics and multiples for Torrent Pharmaceuticals

Key valuation ratios for Torrent Pharmaceuticals help frame the ex-dividend trading in India, with consolidated data from Moneycontrol indicating that investors commonly track metrics such as the trailing price-to-earnings ratio, price-to-book value and return on equity for the company on an ongoing basis.

While exact multiples move with the share price, the company’s placement in the Pharmaceuticals & Drugs peer group on the NSE and BSE means its valuation is often compared with other large Indian drug makers, with analysts and investors assessing whether its earnings, margin profile and dividend stream justify any premium or discount to domestic sector averages.

Conclusion

The ex-dividend trading of Torrent Pharmaceuticals shares on 05/29/2026 with a ?9 per share final dividend puts the focus on the company’s cash distribution record and how it is priced into the stock on Indian exchanges.

Against this backdrop, commonly watched valuation indicators such as earnings multiples and return metrics frame the discussion around whether the current share price reflects the company’s profitability profile and growth prospects in the domestic and international pharmaceuticals market.

Investors will continue to monitor subsequent corporate updates, derivatives activity and sector dynamics in India to gauge how the post-dividend valuation of Torrent Pharmaceuticals evolves over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.